Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 450B 4.71B 4.09B 3.81B 3.5B 6.61B 6.71B 44.91B 17.63B 224B 17.68B 17.3B 750B P/E 2027 *
39.1x
P/E 2028 * 34.7x
Enterprise Value 450B 4.71B 4.09B 3.81B 3.5B 6.61B 6.71B 44.91B 17.63B 224B 17.68B 17.3B 750B EV / Sales 2027 *
10.7x
EV / Sales 2028 * 9.67x
Free-Float
24.37%
Yield 2027 *
1.11%
Yield 2028 * 1.11%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day+1.68%
1 week+5.58%
1 month+8.26%
3 months+13.61%
6 months+10.68%
Current year+7.39%
1 week 2,494.7
Extreme 2494.7
2,675.1
1 month 2,370.65
Extreme 2370.65
2,675.1
Current year 2,088
Extreme 2088
2,715.15
1 year 2,088
Extreme 2088
2,935.85
3 years 1,387.9
Extreme 1387.9
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 30/11/2022
Director of Finance/CFO - 31/03/2026
Chief Tech/Sci/R&D Officer - 07/07/2024
Director TitleAgeSince
Director/Board Member 64 06/04/2017
Chairman 73 31/03/2019
Director/Board Member 59 17/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.68%+5.58%-15.98%+89.80% 4.71B
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.08%-0.52%+25.50%+53.76% 357.85B
Weighted average by Cap. -0.98%-1.92%+39.17%+72.98%

Financials

2027 *2028 *
Net sales 41.99B 440M 382M 356M 327M 617M 627M 4.2B 1.65B 20.9B 1.65B 1.62B 70.09B 46.49B 487M 423M 394M 362M 683M 694M 4.64B 1.82B 23.14B 1.83B 1.79B 77.61B
Net income 11.42B 120M 104M 96.77M 88.85M 168M 170M 1.14B 448M 5.68B 449M 439M 19.06B 12.54B 131M 114M 106M 97.61M 184M 187M 1.25B 492M 6.24B 493M 483M 20.94B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
31/07/26 ₹2,653.45 +1.68% 2,858
30/07/26 ₹2,609.65 -0.67% 2,303
29/07/26 ₹2,627.35 -0.52% 6,448
28/07/26 ₹2,641.20 +3.57% 4,963
27/07/26 ₹2,550.20 +1.47% 2,697
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,653.45INR
Average target price
2,969.75INR
Spread / Average Target
+11.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock